The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul‐de‐sac?
Open accessAbstract
Objective: Negative symptoms of schizophrenia are debilitating and they contribute to poor outcome in schizophrenia. Initial enthusiasm that second‐generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest. Method: A review of the current ‘state‐of‐play’ of pharmacological treatments for negative symptoms in schizophrenia. Results: Treatment results to date have been largely disappointing. The evidence for efficacy of second‐generation antipsychotics is reviewed. Conclusion: The measurement and treatment trials methodology for the evaluation of negative symptoms need additional refinement before therapeutic optimism that better treatments for negative symptoms can be realized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Negative symptoms of schizophrenia: a problem that will not go away
Stahl, S. M., & Buckley, P. F. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00947.x · Cited by 195 · cited 2×
“It suggests that the actions of low-dose olanzapine on deficit state negative symptoms could be due to those pharmacological properties of this drug that are more potent than its traditional blockade of D2 dopamine receptors and therefore more potently active at low doses, especially actions at serotonin receptors (2,…”
BackgroundSelf-citation
Cited by
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Gold, C., Solli, H. P., Krüger, V., & Lie, S. A. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.01.001 · Cited by 417
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
An integrative perspective on the role of dopamine in schizophrenia
Maia, T. V., & Frank, M. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.021 · Cited by 293
Metadata
- Authors
- Buckley, P. F., & Stahl, S. M.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2007-01-15
- Volume
- 115
- Issue
- 2
- Pages
- 93-100
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2045658109
- Cited by
- 163
- References
- 2
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul‐de‐sac? https://app.cochat.ai/papers/10.1111/j.1600-0447.2007.00992.x
- The paper
- Buckley, P. F., & Stahl, S. M. (2007). Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul‐de‐sac? Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2007.00992.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.